Countdown To October: Inhibrx Awaits Ozekibart Clinical Data

Inhibrx Biosciences (INBX) is poised for a significant catalyst in late October 2025 with the anticipated unblinding of its registration-enabling Phase II ChonDRAgon trial for Ozekibart, a DR5 agonist antibody, in conventional chondrosarcoma. Concurrently, interim data from a Phase I trial for Ozekibart in Ewing sarcoma and colorectal cancer are also expected. This clinical data release is a key focus for investors, given the company's $186.6 million in cash and equivalents as of June 30, 2025, and its stock currently trading at $23.31.

Analysis

Inhibrx Biosciences (INBX) faces a pivotal, catalyst-driven period centered on its lead clinical candidate, Ozekibart, with key data expected by late October 2025. The primary event is the unblinding of the registration-enabling Phase II ChonDRAgon trial in conventional chondrosarcoma, which is contingent upon reaching 151 progression-free survival events. The term "registration-enabling" implies that positive results could form the basis for a regulatory submission, representing a significant value inflection point. Concurrently, the company anticipates releasing interim Phase I data for Ozekibart in Ewing sarcoma and colorectal cancer, adding another layer to the data readout. Financially, Inhibrx reported a cash position of $186.6 million as of June 30, 2025, providing an operational runway through this critical period. The market has already reacted with anticipation, as the stock has appreciated from $18.35 on July 8 to its current price of $23.31, indicating that a degree of positive expectation is already priced into the valuation.

Key Decisions for Investors

• Investors should view the late October 2025 data release for Ozekibart as a significant binary event, where the stock's recent run-up to $23.31 suggests heightened downside risk should trial results disappoint.
• Given the speculative nature and the stock's recent appreciation, existing holders might consider trimming positions or employing hedging strategies to manage risk ahead of the high-impact announcement.
• It is critical to monitor company communications regarding the achievement of the 151 progression-free survival events, as this is the direct trigger for the ChonDRAgon trial unblinding.
• While the company's $186.6 million cash position provides a near-term buffer, the outcome of the Ozekibart trials will be the primary determinant of its future financing needs and long-term valuation.